Zamboni WC - Search Results

1

A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma.

Zamboni WC, Gajjar AJ, Mandrell TD, Einhaus SL, Danks MK, Rogers WP, Heideman RL, Houghton PJ, Stewart CF. Zamboni WC, et al. Clin Cancer Res. 1998 Oct;4(10):2537-44. Clin Cancer Res. 1998. PMID: 9796988

2

Topoisomerase I interactive drugs in children with cancer.

Stewart CF, Zamboni WC, Crom WR, Gajjar A, Heideman RL, Furman WL, Meyer WH, Houghton PJ, Pratt CB. Stewart CF, et al. Among authors: zamboni wc. Invest New Drugs. 1996;14(1):37-47. doi: 10.1007/BF00173681. Invest New Drugs. 1996. PMID: 8880392 Review.

3

Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.

Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, Winick N, Santana VM, Dryer ZA, Kurtzberg J, Bell B, Grier H, Vietti TJ. Tubergen DG, et al. Among authors: zamboni wc. J Pediatr Hematol Oncol. 1996 Nov;18(4):352-61. doi: 10.1097/00043426-199611000-00004. J Pediatr Hematol Oncol. 1996. PMID: 8888741 Clinical Trial.

4

Schedule-dependent efficacy of camptothecins in models of human cancer.

Houghton PJ, Stewart CF, Zamboni WC, Thompson J, Luo X, Danks MK, Houghton JA. Houghton PJ, et al. Among authors: zamboni wc. Ann N Y Acad Sci. 1996 Dec 13;803:188-201. doi: 10.1111/j.1749-6632.1996.tb26388.x. Ann N Y Acad Sci. 1996. PMID: 8993512 No abstract available.

5

Efficacy of oral irinotecan against neuroblastoma xenografts.

Thompson J, Zamboni WC, Cheshire PJ, Richmond L, Luo X, Houghton JA, Stewart CF, Houghton PJ. Thompson J, et al. Among authors: zamboni wc. Anticancer Drugs. 1997 Apr;8(4):313-22. doi: 10.1097/00001813-199704000-00002. Anticancer Drugs. 1997. PMID: 9180383

6

Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice.

Stewart CF, Zamboni WC, Crom WR, Houghton PJ. Stewart CF, et al. Among authors: zamboni wc. Cancer Chemother Pharmacol. 1997;40(3):259-65. doi: 10.1007/s002800050656. Cancer Chemother Pharmacol. 1997. PMID: 9219511

7

Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion.

Zamboni WC, Houghton PJ, Johnson RK, Hulstein JL, Crom WR, Cheshire PJ, Hanna SK, Richmond LB, Luo X, Stewart CF. Zamboni WC, et al. J Pharmacol Exp Ther. 1998 Jan;284(1):89-94. J Pharmacol Exp Ther. 1998. PMID: 9435165

8

Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study.

Saylors RL 3rd, Stewart CF, Zamboni WC, Wall DA, Bell B, Stine KC, Vietti TJ. Saylors RL 3rd, et al. Among authors: zamboni wc. J Clin Oncol. 1998 Mar;16(3):945-52. doi: 10.1200/JCO.1998.16.3.945. J Clin Oncol. 1998. PMID: 9508177 Clinical Trial.

9

Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.

Zamboni WC, Houghton PJ, Thompson J, Cheshire PJ, Hanna SK, Richmond LB, Lou X, Stewart CF. Zamboni WC, et al. Clin Cancer Res. 1998 Feb;4(2):455-62. Clin Cancer Res. 1998. PMID: 9516936

10

Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.

Zamboni WC, Stewart CF, Cheshire PJ, Richmond LB, Hanna SK, Luo X, Poquette C, McGovren JP, Houghton JA, Houghton PJ. Zamboni WC, et al. Clin Cancer Res. 1998 Mar;4(3):743-53. Clin Cancer Res. 1998. PMID: 9533544

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

164 results

Search Page

Filters